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EDITORIAL
Caveolar cohabitation
Imagine trying to arrest a criminal holed up in a moun- One example will suffice, which is drawn from a model
tain stronghold surrounded by his henchmen. One option proposed by Goligorsky [4]. Nitric oxide terminates en-
would be to carry a picture of the accused and compare dothelin signaling. Nitric oxide donors also cause oligo-
it with the faces of everyone you encountered until the meric caveolin to be converted to monomeric caveolin,
right match occurred. (In biology, this is how a ligand which is evidence of caveolar disruption. Cyclic guano-
finds its receptor—it “recognizes” it.) Perhaps a more sine monophosphate (cGMP) does the same thing to
productive approach would be to locate the culprit and caveolae, as does bradykinin, in an endothelial nitric
his henchmen in a cave and then to roll a large stone oxide synthase (eNOS)–dependent manner. Since nitric
over the opening of the cave, thereby immobilizing the oxide (NO) donors also affect the state of tyrosine phos-
entire force who, after all, have the same sinister purpose. phorylation of focal adhesion kinase and paxillin and
(In biology, receptors and their henchmen, the signaling negatively regulate protein kinase Cd activity, NO could
molecules, seem to cohabit in caves, as we will see.) influence the turnover of adhesions, cell motility, and
Now, translate this strategy to an intervention in the cell-matrix interaction via an effect on caveolar integrity
setting of glomerular inflammation. If you could identify [5]. Thus, by dissociating oligomeric caveolin and dis-
the mountain (the mesangial cell) in which the cave (ca- tancing signaling molecules from each other (eNOS, G
veola) is located and which contains the major criminal protein, receptor), the signaling cascade is disrupted. The
element [a cytokine or growth factor such as platelet- model suggests that a ubiquitous mediator such as NO,
derived growth factor (PDGF)] accused of being instru- in the right concentration and locality, should interfere
mental in damaging the glomerulus, then, rather than with a composite set of signaling pathways that originate
targeting only the single cytokine receptor, could you in the caveolar membranes. That such pathways are se-
try to close off the whole cave and thereby immobilize lective for specific receptors is highlighted by the fact
the whole band of cytokine receptors and signaling mole- that Tamai et al found that transforming growth factor-b
cules, all intent on the same end? (TGF-b) receptors do not localize in caveolae in mesan-
In this issue of Kidney International, Tamai and col- gial cells but are found in a noncaveolar compartment
leagues describe their finding that mesangial cells contain [1]. Thus, agents that target caveolar function should be,
caveolae that integrate PDGF receptors within their to some extent, selective and, if caveolae are easier to
walls and that the main protein building block of caveo- target than their contents (for example, receptors), this
lae, caveolin-1, is up-regulated in a model of experimen- represents an avenue for intervention in disease states.
tal mesangial proliferative nephritis in the rat kidney [1]. Now, back to the mountain, the cave, and the criminal.
Caveolae are flask-shaped plasma membrane invagi- Is it possible to envisage a therapeutic strategy for the
nations that contain a variety of signal transduction mole- future that could negate the proliferative effects of
cules and receptors for growth factors and cytokines. PDGF and its accomplices on mesangial cells in glomeru-
They internalize molecules by forming invaginations and lar diseases in which this proliferation contributes to loss
then return to the plasma membrane cyclically [2]. When of function? The model of anti-Thy1 nephritis that Tamai
a growth factor such as PDGF, which is strongly mito- et al studied is just such a disease. Following a phase of
genic for mesangial cells and probably plays a role in mesangolysis, restitution of the mesangium is thought to
cell proliferation in inflamed glomeruli, seeks out and take place by mesangial cell proliferation [6]. If one
binds to its plasma membrane receptor, these receptors predominant change which takes place in these kidneys
move into caveolar membranes where they aggregate [3]. is an up-regulation of caveolae in mesangial cells, it may
Why should this be any more effective than the receptors be possible to suppress not only the PDGF effect on
being distributed randomly throughout the plasma mem- proliferation but also the effects of other culprit recep-
brane? The answer lies in the identity of the molecules tors and signaling molecules that cohabit with the PDGF
that cohabit with PDGF receptors in the caveolae. receptor in this very well-contained organelle. Such re-
ceptors include muscarinic, bradykinin, b-adrenergic and
AT1 receptors. Caveolin-1 can be viewed as the organiz-Key words: glomerular inflammation, mesangial cells, platelet-derived
growth factors (PDGF), caveolin-1 ing molecule for such receptors.
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